24/7 Market News Snapshot 12 August, 2025 – ProPhase Labs, Inc. Common Stock (DE) (NASDAQ:PRPH)

August 12, 2025

DENVER, Colo., 12 August, 2025 (www.247marketnews.com) – (Nasdaq:PRPH) are discussed in this article.
ProPhase Labs, Inc. (Nasdaq:PRPH) has recently captured significant market attention, experiencing a remarkable increase in its share price, surpassing its previous close by nearly 47.67%, trading at approximately $0.416 in pre-market activity with a substantial volume of 30.07 million shares. This surge reflects heightened investor interest and confidence in the company’s future prospects.

In addition to its rising stock performance, ProPhase has achieved a critical milestone in its product development. The company proudly announced the issuance of U.S. Patent No. 12379378-B2, which secures its innovative biomarker-driven systems and methodologies related to the BE-Smart™ molecular diagnostic test. This test is designed to assess the risk of progression for Barrett’s esophagus and esophageal adenocarcinoma, making strides in early disease detection and patient management.

The validation of the BE-Smart™ test, boasting a technical success rate of over 95%, underscores its effectiveness in both esophageal brush cytology and forceps biopsies. By utilizing the strengths of both sampling techniques, the BE-Smart™ test aims to substantially enhance risk stratification and early diagnosis for patients suffering from gastroesophageal reflux disease (GERD) and other related issues.

The patent encompasses key biomarkers, including ISG15 and S100P, which demonstrate ProPhase’s commitment to advancing personalized medicine. CEO Ted Karkus highlighted the importance of the patent, stating it propels the company towards transforming clinical practices for esophageal cancer. He expressed optimism about accelerating commercialization efforts and expanding access to BE-Smart™, marking a significant advancement in the company’s innovative endeavors.

As ProPhase Labs continues to progress in biotechnology, it is steadfast in its mission to deliver innovative diagnostics and actionable insights that contribute to a healthier global community.

Related news for (PRPH)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.